Related Experiment Video
Updated: Mar 26, 2026
04:56
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
Published on: August 4, 2023
1.3K
Anticoagulation Therapy in Traumatic Brain Injury
Tomasz Tykocki1, Krystyna Guzek2
1Department of Neurosurgery, Institute of Psychiatry and Neurology, Warsaw, Poland.
World Neurosurgery
|February 7, 2016
Summary
Managing anticoagulation therapy (AT) after traumatic brain injury (TBI) is complex. New oral anticoagulants show a lower risk of intracranial hemorrhage compared to warfarin in TBI patients.
Area of Science:
- Neurology
- Neurosurgery
- Pharmacology
Background:
- Anticoagulation therapy (AT) management in traumatic brain injury (TBI) is challenging.
- Limited data exist, necessitating expert opinion for clinical decisions.
- Perioperative AT and antiplatelet strategies require critical assessment.
Purpose of the Study:
- To critically evaluate therapeutic options for anticoagulation and antiplatelet agents in the perioperative period following TBI.
- To summarize current evidence regarding anticoagulation management in TBI patients.
Main Methods:
- A comprehensive literature review was conducted.
- Relevant data on anticoagulation therapy in TBI patients were summarized.
Main Results:
- Patients on preinjury AT with TBI face risks of thromboembolic complications and hematoma expansion.
- New oral anticoagulants (NOACs) demonstrate a lower incidence of intracranial hemorrhage than warfarin.
- Intracranial hemorrhage rates are significantly lower with NOACs or heparin compared to vitamin K antagonists.
Conclusions:
- NOACs may represent a safer alternative to warfarin in TBI patients requiring anticoagulation.
- Further research is needed to establish optimal AT protocols for TBI.
- Careful consideration of anticoagulation strategies is crucial for improving outcomes in TBI patients.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
460
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
460
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:30Venous Thrombosis IV: Nursing Management
371
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
371